$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000117891314000149 Filed on January 14, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2012 Q4
Revenue	$0.00	$67.00K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$510.0K	$420.0K	$340.0K
YoY Change	0.0%	23.53%	21.43%
% of Gross Profit
Research & Development	$674.0K	$750.0K	$392.6K
YoY Change	-10.01%	91.02%	113.37%
% of Gross Profit
Depreciation & Amortization	$0.00	$2.000K	$2.271K
YoY Change		-11.93%	-62.41%
% of Gross Profit
Operating Expenses	$674.0K	$750.0K	$392.6K
YoY Change	-10.01%	91.02%	113.37%
Operating Profit	-$1.186M	-$1.168M	-$731.8K
YoY Change	-5.86%	59.6%	57.07%
Interest Expense	$70.00K	$40.00K	-$230.0K
YoY Change	133.33%	-117.39%	2200.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.115M	-$1.124M	-$958.8K
YoY Change	-9.06%	17.27%	100.36%
Income Tax
% Of Pretax Income
Net Earnings	-$1.115M	-$1.124M	-$958.8K
YoY Change	-9.04%	17.24%	100.36%
Net Earnings / Revenue		-1677.61%
Basic Earnings Per Share
Diluted Earnings Per Share	-$121.6K	-$141.1K	-$140.6K
COMMON SHARES
Basic Shares Outstanding	9.745M shares	7.948M shares	86.51M
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q4	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.35M	$7.790M	$6.600M
YoY Change	337.27%	18.03%	79.35%
Cash & Equivalents	$3.253M	$1.371M	$5.531M
Short-Term Investments	$20.10M	$6.420M	$1.060M
Other Short-Term Assets	$270.0K	$190.0K	$40.00K
YoY Change	350.0%	375.0%	0.0%
Inventory
Prepaid Expenses			$18.80K
Receivables			$75.95K
Other Receivables	$73.05K		$99.53K
Total Short-Term Assets	$23.69M	$7.986M	$6.808M
YoY Change	298.81%	17.31%	76.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.16K	$8.792K	$2.497K
YoY Change	550.83%	252.1%	-77.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$10.00K
YoY Change	-100.0%	-100.0%	0.0%
Other Assets	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$23.06K	$19.22K	$16.98K
YoY Change	28.61%	13.18%	-54.23%
TOTAL ASSETS
Total Short-Term Assets	$23.69M	$7.986M	$6.808M
Total Long-Term Assets	$23.06K	$19.22K	$16.98K
Total Assets	$23.71M	$8.006M	$6.825M
YoY Change	298.0%	17.3%	74.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$300.0K	$620.0K	$290.0K
YoY Change	-28.57%	113.79%	-19.44%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$349.8K	$668.5K	$334.6K
YoY Change	-25.47%	99.83%	-21.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$30.00K	$30.00K	$240.0K
YoY Change	-87.5%	-87.5%	50.0%
Total Long-Term Liabilities	$32.42K	$31.89K	$240.4K
YoY Change	-86.49%	-86.74%	49.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$349.8K	$668.5K	$334.6K
Total Long-Term Liabilities	$32.42K	$31.89K	$240.4K
Total Liabilities	$382.2K	$700.4K	$575.0K
YoY Change	-46.11%	21.81%	-1.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.36M	-$23.25M	-$18.85M
YoY Change	21.35%	23.33%	25.45%
Common Stock	$46.84M	$30.22M	$24.86M
YoY Change	86.78%	21.53%	35.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.33M	$7.305M	$6.250M
YoY Change
Total Liabilities & Shareholders Equity	$23.71M	$8.006M	$6.825M
YoY Change	298.0%	17.3%	74.88%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2012 Q4
OPERATING ACTIVITIES
Net Income	-$1.115M	-$1.124M	-$958.8K
YoY Change	-9.04%	17.24%	100.36%
Depreciation, Depletion And Amortization	$0.00	$2.000K	$2.271K
YoY Change		-11.93%	-62.41%
Cash From Operating Activities	-$1.480M	-$748.0K	-$792.8K
YoY Change	15.63%	-5.65%	63.78%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$5.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$13.12M		$154.00
YoY Change	496.36%		-85.49%
Cash From Investing Activities	-$13.13M	-$162.0K	$454.2K
YoY Change	496.82%	-135.66%	1.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	16.49M		$1.458M
YoY Change	-165000.0%
NET CHANGE
Cash From Operating Activities	-1.480M	-$748.0K	-$792.8K
Cash From Investing Activities	-13.13M	-$162.0K	$454.2K
Cash From Financing Activities	16.49M		$1.458M
Net Change In Cash	1.880M	-$910.0K	$1.120M
YoY Change	-153.87%	-181.26%	-3287.6%
FREE CASH FLOW
Cash From Operating Activities	-$1.480M	-$748.0K	-$792.8K
Capital Expenditures	-$10.00K	$5.000K
Free Cash Flow	-$1.470M	-$753.0K	-$792.8K
YoY Change	14.84%	-5.02%	63.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	dei	Amendment Flag AmendmentFlag	false
CY2011	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	502593	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	200866	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	562966	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	917809	USD
CY2013Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
CY2013Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2013Q4	dei	Document Period End Date DocumentPeriodEndDate	2013-11-30
CY2013Q4	dei	Document Type DocumentType	10-Q
CY2013Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001176309
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9745166	shares
CY2013Q4	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q4	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
CY2013Q4	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	2731	USD
	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	177782	USD
CY2008	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	203982	USD
CY2009	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	117174	USD
CY2010	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	116944	USD
CY2011	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	26733	USD
CY2012	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	70292	USD
CY2013	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	156253	USD
	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	8437	USD
CY2008	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2009	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2010	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2011	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3782	USD
CY2013Q1	ormp	Common Stock Shares Authorized Prior To Reverse Stock Split CommonStockSharesAuthorizedPriorToReverseStockSplit	200000000	shares
CY2013Q1	ormp	Common Stock Shares Issued Prior To Reverse Stock Split CommonStockSharesIssuedPriorToReverseStockSplit	86500000	shares
CY2013Q1	ormp	Common Stock Shares Outstanding Prior To Reverse Stock Split CommonStockSharesOutstandingPriorToReverseStockSplit	86500000	shares
CY2013Q4	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
CY2012Q4	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature	108000	USD
CY2013Q4	ormp	Finders Fee Shares FindersFeeShares	13872	shares
CY2011	ormp	Finders Fee Shares FindersFeeShares	13872	shares
CY2013Q4	ormp	Imputed Interest Expense ImputedInterestExpense		USD
	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	98750	USD
CY2012Q4	ormp	Imputed Interest Expense ImputedInterestExpense		USD
	ormp	Imputed Interest Expense ImputedInterestExpense	23559	USD
CY2013Q4	ormp	Long Term Purchase Commitment Amount To Be Paid After Milestone Achievement LongTermPurchaseCommitmentAmountToBePaidAfterMilestoneAchievement	332702	USD
CY2013Q4	ormp	Marketable Securities Sold MarketableSecuritiesSold	1025989	shares
CY2013Q4	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
CY2012Q4	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances	6061	USD
CY2013Q4	ormp	Professional Fees Amount Paid For Milestones ProfessionalFeesAmountPaidForMilestones	196304	USD
CY2008	ormp	Receipts On Account Of Shares And Warrants ReceiptsOnAccountOfSharesAndWarrants	6061	USD
	ormp	Shares Cancelled Value SharesCancelledValue		USD
CY2013	ormp	Stock Issued During Period Value Marketable Securities StockIssuedDuringPeriodValueMarketableSecurities	628630	USD
	ormp	Stock Issued During Period Value Offering Costs StockIssuedDuringPeriodValueOfferingCosts		USD
CY2013Q4	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	64400	USD
CY2008	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	116110	USD
CY2009	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	152928	USD
CY2010	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	249850	USD
CY2011	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	227569	USD
CY2012	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	107860	USD
CY2013	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	244457	USD
CY2009	ormp	Stock Issued During Period Value Services To Be Rendered StockIssuedDuringPeriodValueServicesToBeRendered	203699	USD
CY2012	ormp	Stock Issued During Period Value Shares To Be Issued StockIssuedDuringPeriodValueSharesToBeIssued	25093	USD
CY2013Q4	ormp	Warrants Exchanged WarrantsExchanged		USD
CY2012Q4	ormp	Warrants Exchanged WarrantsExchanged	296982	USD
	ormp	Warrants Exchanged WarrantsExchanged	296982	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	621274	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	450941	USD
CY2013Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	282807	USD
CY2013Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2013Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	334173	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	303403	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	30123592	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	29855723	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18991	USD
CY2013Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	200858	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1968547	USD
CY2008	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	459467	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	436025	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	690882	USD
CY2013Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
CY2012Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	USD
CY2013Q4	us-gaap	Assets Assets	8005628	USD
CY2013Q3	us-gaap	Assets Assets	8660182	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	7986413	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	8644276	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18454	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1370753	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5531075	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2272228	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4430740	USD
CY2002Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1513365	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-901475	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1100335	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1370753	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16666667	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16666667	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7947872	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7937872	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7200000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7947872	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7937872	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7200000	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	95358	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	95238	USD
CY2013Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1093550	USD
CY2012Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-722885	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22913736	USD
CY2013Q4	us-gaap	Contribution Of Property ContributionOfProperty		USD
CY2012Q4	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty	18991	USD
CY2013Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		USD
CY2012Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	917809	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	917809	USD
CY2013Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	5459254	USD
CY2013Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	5246627	USD
CY2013Q4	us-gaap	Depreciation Depreciation	1871	USD
CY2012Q4	us-gaap	Depreciation Depreciation	2271	USD
	us-gaap	Depreciation Depreciation	128094	USD
CY2013Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		USD
CY2012Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	44699	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-98005	USD
CY2013Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	5097	USD
CY2013Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	4530	USD
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.14
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.14
CY2013Q4	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	9420	USD
CY2012Q4	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-19502	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-18791	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.106	pure
CY2013Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	21832	USD
CY2012Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-18782	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-28384	USD
CY2013Q4	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2012Q4	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments	1033004	USD
CY2013Q4	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	18454	USD
CY2012Q4	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1102161	USD
CY2013Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	417727	USD
CY2012Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	339213	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10611403	USD
CY2013Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1124320	USD
CY2012Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-958753	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23212195	USD
CY2013Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2012Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35714	USD
CY2013Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	170333	USD
CY2012Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-309870	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	621274	USD
CY2013Q4	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
CY2012Q4	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	23210	USD
CY2013Q4	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	674	USD
CY2012Q4	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	5215	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	21905	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-958753	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23247909	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4478917	USD
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-2769271	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-2760474	USD
CY2013Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	24969	USD
CY2012Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20962	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	188222	USD
CY2013Q4	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
CY2012Q4	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	2615	USD
CY2013Q4	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
CY2012Q4	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	16000	USD
CY2013Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	4593	USD
CY2013Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	4593	USD
CY2013Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	64400	USD
CY2012Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1464813	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8005628	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8660182	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	668526	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	498193	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	31888	USD
CY2013Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	31214	USD
CY2013Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	23210	USD
CY2013Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	23210	USD
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	962392	USD
CY2013Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	956376	USD
CY2013Q4	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> <!--StartFragment--> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr valign="top"> <td style="WIDTH: 18pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> a.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: left"> General:</div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div> <div style="TEXT-ALIGN: left; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr valign="top"> <td style="WIDTH: 72pt"> </td> <td style="WIDTH: 18pt" align="right"> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> 1)</div> </td> <td align="left"> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> Incorporation and operations</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. In subsequent periods, the Company entered into additional development agreements with Hadasit, the most recent of which was signed on September 11, 2011, see also note 2a.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary"), (together with the Company, "the Group").</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd ("Entera") to D.N.A Biomedical Solutions Ltd ("D.N.A"), other than a 3% interest, which is accounted for as a cost method investment (amounting to $1,027 as of the end of the period). In consideration for the shares sold to D.N.A, the Company received a promissory note issued by D.N.A in the principal amount of $450,000, with an annual interest rate of 0.45%, that was paid in full in November 2011, and 8,404,667 ordinary shares of D.N.A, see also note 4.</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010.  Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera's net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of November 30, 2013, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr valign="top"> <td style="WIDTH: 72pt"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">  </div> </td> <td style="WIDTH: 18pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> 2)</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: left"> Development and liquidity risks</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.</div> <div style="MARGIN-LEFT: 446pt; DISPLAY: block; TEXT-INDENT: 0pt"> <br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities" due to the fact that it has not generated any revenues from its operations.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"> <font style="FONT-SIZE: 10pt; DISPLAY: inline">Based on its current cash resources and commitments as of November 30, 2013, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months. See also note 6a, with respect to the Company's offering</font> in December 2013.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr valign="top"> <td style="WIDTH: 72pt"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">  </div> </td> <td style="WIDTH: 18pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> 3)</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: left"> Reverse stock split</div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 90pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> On January 10, 2013, the Company's Board of Directors approved a reverse stock split at a ratio of one-for-twelve, effective January 22, 2013, which decreased the number of common shares issued and outstanding as of January 23, 2013, from approximately 86.5 million shares to approximately 7.2 million shares and the number of authorized common shares from 200 million shares to approximately 16.7 million shares. All share and per share amounts included in the consolidated financial statements have been adjusted retroactively to reflect the effects of the reverse stock split.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div> <!--EndFragment--></div> </div>
CY2013Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		USD
CY2012Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1458436	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21316432	USD
CY2013Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-162187	USD
CY2012Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	454227	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4897459	USD
CY2013Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-748708	USD
CY2012Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-792826	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15029429	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-1124320	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	434876	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-2977376	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-1561245	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-3344478	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4231812	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1168237	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-731839	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23601277	USD
CY2013Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5322	USD
CY2012Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	117347	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	136167	USD
CY2013Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	30770	USD
CY2012Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	235868	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	334173	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	303403	USD
CY2013Q4	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	18454	USD
CY2012Q4	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax		USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	108824	USD
CY2013Q4	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	43902	USD
CY2012Q4	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	118521	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	306830	USD
CY2013Q4	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2206	USD
CY2012Q4	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	299158	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	696032	USD
CY2013Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	46123	USD
CY2012Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	72244	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	433776	USD
CY2013Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent		USD
CY2013Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	58412	USD
CY2013Q4	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1		USD
CY2012Q4	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	628630	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	628630	USD
CY2013Q4	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2012Q4	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2013Q4	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
CY2012Q4	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	381666	USD
CY2013Q4	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	500	USD
CY2012Q4	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	154	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-10582011	USD
CY2013Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4895	USD
CY2012Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	136886	USD
CY2013Q4	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4300000	USD
CY2012Q4	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	16050363	USD
CY2013Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	8678	USD
CY2013Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	8004	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	172917	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	90103	USD
CY2013Q4	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	5830	USD
CY2013Q3	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	5545	USD
CY2013Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
CY2012Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	275000	USD
CY2013Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		USD
CY2012Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1458436	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	20859553	USD
CY2013Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
CY2012Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	120000	USD
CY2013Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
CY2012Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	66243	USD
CY2013Q4	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	43208	USD
CY2013Q4	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	4100000	USD
CY2012Q4	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	454381	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	-9485	USD
CY2013Q4	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	43208	USD
CY2012Q4	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments		USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	719879	USD
CY2013Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		USD
CY2012Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	109575	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8792	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	109575	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5768	USD
CY2013Q4	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
CY2012Q4	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	120000	USD
CY2013Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	750510	USD
CY2012Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	392626	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12554998	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	16000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23247909	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22123589	USD
CY2013Q4	us-gaap	Share Based Compensation ShareBasedCompensation	203589	USD
CY2012Q4	us-gaap	Share Based Compensation ShareBasedCompensation	218208	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5894095	USD
CY2013Q4	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	10000	shares
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	7305214	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	8130775	USD
CY2007Q3	us-gaap	Stockholders Equity StockholdersEquity	513131	USD
CY2002Q2	us-gaap	Stockholders Equity StockholdersEquity	53700	USD
CY2008Q3	us-gaap	Stockholders Equity StockholdersEquity	4593060	USD
CY2009Q3	us-gaap	Stockholders Equity StockholdersEquity	2746192	USD
CY2010Q3	us-gaap	Stockholders Equity StockholdersEquity	830272	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	3723916	USD
CY2013	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	12	pure
CY2013Q4	us-gaap	Stock Issued1 StockIssued1		USD
CY2012Q4	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	77779	USD
CY2008	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	275000	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	4238889	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2122981	USD
CY2008	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5784800	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3694212	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2944464	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1422592	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	434876	USD
CY2013Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7941059	shares
CY2012Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6828896	shares

Files In Submission

Name	View Source	Status
0001178913-14-000149-index-headers.html	Edgar Link	pending
0001178913-14-000149-index.html	Edgar Link	pending
0001178913-14-000149.txt	Edgar Link	pending
0001178913-14-000149-xbrl.zip	Edgar Link	pending
exhibit_10-1.htm	Edgar Link	pending
exhibit_31-1.htm	Edgar Link	pending
exhibit_31-2.htm	Edgar Link	pending
exhibit_32-1.htm	Edgar Link	pending
exhibit_32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ormp-20131130.xml	Edgar Link	completed
ormp-20131130.xsd	Edgar Link	pending
ormp-20131130_cal.xml	Edgar Link	unprocessable
ormp-20131130_def.xml	Edgar Link	unprocessable
ormp-20131130_lab.xml	Edgar Link	unprocessable
ormp-20131130_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zk1414207.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2014 Q1 Form 10-Q Financial Statement

#000117891314000149 Filed on January 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2014 Q1 Form 10-Q Financial Statement

#000117891314000149 Filed on January 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp